Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 7/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 7/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6171571 | 0.83 | GRM5 (0.43) | KDM1A | |
| SCHEMBL6171901 | 0.74 | ALOX5AP (0.39) | PAX8 | |
| SCHEMBL29809001 | 0.70 | CYP11B2 (0.71) | CYP11B2CHRNB2CHRNA5CHRNA4MKNK1 | |
| SCHEMBL13537172 | 0.70 | CYP11B2 (0.71) | CYP11B2CHRNB2CHRNA5CHRNA4MKNK1 | |
| SCHEMBL6168448 | 0.67 | ATR (0.52) | CYP11B2CYP11B1ATR | |
| SCHEMBL14082560 | 0.67 | CYP11B2 (0.65) | CYP11B2MKNK1MKNK2CYP11B1ATR | |
| SCHEMBL6188982 | 0.64 | CYP11B2 (1.00) | CYP11B2CHRNB2CHRNA5CHRNA4MKNK1 | |
| SCHEMBL30712752 | 0.64 | CYP11B2 (1.00) | CYP11B2CHRNB2CHRNA5CHRNA4MKNK1 | |
| SCHEMBL4331170 | 0.62 | CYP3A4 (0.67) | CYP11B2CHRNB2CHRNA5CHRNA4CYP11B1 | |
| SCHEMBL1690481 | 0.62 | CYP11B2 (0.68) | CYP11B2CHRNB2CHRNA5CHRNA4MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254136-A4 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD (KR) | 2005-06-01 | — | — | EP | disclosed |
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | LG CHEM INVESTMENT LTD. (KR) | 2003-04-03 | — | — | US | disclosed |
| EP-1254136-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG Chem Investment, Ltd. (KR) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055146-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | F2, F12, TFPI | CYP11B2 617/4885SCN9A 1232/4885CHRNB2 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.